 On June 29, 2020, Burning Rock Biotech Limited BNR announced a strategic partnership with CStone Pharmaceuticals 2616.HK to co-develop and commercialize companion diagnostics CDx for pralsetinib, an investigational treatment developed by CStones partner Blueprint Medicines, in China for the detection of RET alterations in cancer patients. CStones partner Blueprint Medicines released promising global data for pralsetinib this June at ASCO 2020. 